An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Clinical trial NCT03501615 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT03501615
- Sponsor
- AstraZeneca
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.